Tetraphase Pharmaceuticals, Inc. (TTPH)

[Schnauzer1]

New P3 for cITI (inter-abdominal infection) and second P3 for cUTI (urinary infection) are both planned on highly conservative treatment plans. The replay of cITI is an easy pass and FDA has agreed that it will be bases for drug approval. Label expansion will be based on cUTI trial, which is planned as much more conservative P3 so as to ensure passage (two IV application daily whereas the original failed had three days of once daily IV transitioned to Oral pill)! The stock has taken its hit but should gain value from here as the plan forward is tO gain approval for drug within 16 - 18 months time based on test that has high probability of passing, since it's a repeat of prior passed P3! Time to quadruple down. Adequate cash for trial completion.